Author

P. J. Santangelo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 3 Organism:mouse· 3 Research Focus:drug response / drug discovery· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Assay:CRISPR screen· 1

Frequent Co-Authors

E. L. Blanchard· 3 shared D. M. Shayakhmetov· 2 shared D. Vanover· 2 shared H. E. Peck· 2 shared K. Roy· 2 shared P. Pradhan· 2 shared R. Toy· 2 shared A. Atalis· 1 shared

Activity by Year

2019-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBioengineering

E. L. Blanchard

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Sensitizing solid tumors to CAR-mediated cytotoxicity using synthetic antigens

L. Gamboa, A. H. Zamat, D. Vanover, C. A. Thiveaud, H. E. Peck, H. Phuengkham, A. Sivakumar, A. M. Harris, S. N. Dahotre, F.-Y. Su, P. J. Santangelo, G. A. Kwong

This study develops synthetic antigens to enhance CAR T cell efficacy against solid tumors by reducing off-target effects and improving tumor targeting.

bioRxiv · Dec 11, 2021 · PreprintBioengineering

TRAF6-IRF5 kinetics, TRIF, and biophysical factors drive synergistic innate responses to particle-mediated MPLA-CpG co-presentation

P. Pradhan, R. Toy, N. Jhita, E. L. Blanchard, A. Atalis, B. Pandey, P. J. Santangelo, D. M. Shayakhmetov, K. Roy

This study identifies TRAF6-IRF5 kinetics and TRIF signaling as key drivers of synergistic innate immune responses to MPLA-CpG co-presentation in BM-APCs.

bioRxiv · Jul 17, 2020Immunology

Treating Influenza and SARS-CoV-2 via mRNA-encoded Cas13a

E. L. Blanchard, D. Vanover, S. S. Bawage, P. M. Tiwari, L. Rotolo, J. Beyersdorf, H. E. Peck, N. C. Bruno, R. Hincapie, M. G. Finn, F. Michel, E. R. Lafontaine, R. J. Hogan, C. Zurla, P. J. Santangelo

This study uses mRNA-encoded Cas13a to target and reduce influenza and SARS-CoV-2 RNA in vitro and in a mouse model, showing potential for therapeutic applications.

bioRxiv · Apr 24, 2020 · PreprintBioengineering

Modification of primary amines to higher order amines reduces in vivo hematological and immunotoxicity of cationic nanocarriers through TLR4 and complement pathways

R. Toy, P. Pradhan, V. Ramesh, N. C. Di Paolo, B. Lash, J. Liu, E. L. Blanchard, P. J. Santangelo, D. M. Shayakhmetov, K. Roy

This study shows modifying primary amines to higher order amines reduces toxicity of cationic nanocarriers by targeting TLR4 and complement pathways in vivo.

bioRxiv · May 24, 2019Bioengineering